Little Mix's Jade Thirlwall says she faces a 'daily battle' not to go on Ozempic
In an interview with The Guardian published Saturday, the singer said that many of the negative comments she receives are about weight gain.
"I have a daily battle with myself not to go on Ozempic," Thirlwall told The Guardian. "I don't judge people that do, but because I have a history of eating disorders, I don't know where taking something like that would end for me."
Thirlwall said she had only been out of the hospital for a few months after treatment for anorexia when she auditioned for " The X Factor" in 2011 at 18.
"Historically, if I've ever felt that something is out of my control, then restricting food has been a means of controlling my life in a very toxic way," she said.
Little Mix was formed on "The X Factor" in 2011, comprising Thirlwall, Leigh-Anne Pinnock, Perrie Edwards, and Jesy Nelson. Nelson left the group in 2020 amid backlash over Blackfishing, and in 2022, the band went on hiatus to focus on their solo careers.
Thirlwall said that much of the scrutiny around her body comes from people comparing her to her younger self.
"Now I'm in my 30s and the healthiest I've ever been, but every time I post a picture, there are comments saying, 'She must be pregnant.' The sad thing is that it's usually women," Thirlwall said.
"But people are used to seeing me in a group environment five or 10 years ago when I was stick-thin because I was in my early 20s with an eating disorder," she said.
A representative for Thirlwall did not immediately respond to a request for comment sent by Business Insider outside regular hours.
Ozempic and Wegovy are brand names for semaglutide, an injectable drug originally developed for diabetes. In 2021, the FDA approved semaglutide for use in weight management. The drug works by regulating hunger signals, allowing people to feel full while eating less.
However, it has side effects such as nausea, diarrhea, and constipation. Some patients also reported feeling disgusted by the foods they used to enjoy.
Dr. Francesco Rubino, the chair of metabolic and bariatric surgery at King's College London, told Business Insider in 2022 that it was common for people to regain the weight after stopping treatment.
Several doctors also told Business Insider in July that they've seen a sharp increase in patients on GLP-1 medications when they enter treatment for eating disorders.
In recent years, many Hollywood celebrities have addressed speculation about whether they've used weight-loss drugs.
In May 2023, NBA star Charles Barkley said he lost over 60 pounds in six months after taking Mounjaro while eating healthily and exercising. Later that year, in December 2023, Oprah Winfrey said she uses weight-loss medication to help manage her weight.
Meanwhile, stars such as Lizzo, Kelly Clarkson, and Jesse Plemons, have denied using such medications, attributing their weight loss instead to lifestyle changes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
28 minutes ago
- The Hill
Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers will be able to buy a month's supply of Novo Nordisk's semaglutide pen products for $499 through GoodRx. The list price for a monthly supply of a product like Ozempic is normally around $1,000 or more without insurance. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' GoodRx CEO and President Wendy Barnes said in a statement. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them,' added Barnes. 'It's a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.' This is the most recent in similar moves Novo Nordisk has made to make its popular diabetes and weight loss medication more widely available. Earlier this year, the company announced a direct-to-patient program called NovoCare® Pharmacy for uninsured and underinsured individuals who can pay $499 a month for Wegovy. Novo Nordisk also partnered with online telehealth companies like Ro and LifeMD to sell its pens at the same price point. The telehealth company Hims & Hers was also originally included in the partnership, but Novo Nordisk ended it after accusing the company of illegally selling compounded versions of semaglutide. Hims & Hers maintains it is providing personalized, compounded products within regulatory guidelines. 'Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,' Dave Moore, executive vice president of U.S. operations of Novo Nordisk, said in a statement. 'This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic® self-pay offer for type 2 diabetes patients at an unprecedented price.' Sen. Bernie Sanders (I-Vt.), a prominent critic of high drug costs, called the announcement a 'modest step forward.' 'Novo Nordisk's move to cut the price of Ozempic to $499 for the uninsured is a modest step forward, but let's not forget,' Sanders said on the social media platform X. 'Ozempic costs just $59 in Germany while it costs less than $5 to make. The U.S. must no longer pay the highest prices in the world for prescription drugs.
Business Wire
28 minutes ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Forbes
an hour ago
- Forbes
How Ozempic Impacts Beauty Standards By Changing Your Smile
In an era where social media fuels our obsession with perfection, a new beauty anxiety has emerged from an unexpected source. As GLP-1 drugs like Ozempic promise rapid weight loss, users are discovering that achieving the "ideal" body may come with an unintended trade-off: a transformed smile that doesn't match society's beauty standards. The phenomenon, dubbed "Ozempic mouth," has become increasingly visible as celebrities and influencers showcase dramatic physical changes following prolonged use of these medications. What was once celebrated as a medical breakthrough for weight management has revealed a complex relationship between our pursuit of one beauty ideal and the unintended consequences that can undermine our confidence in other ways. How Your Smile Changes Because Of Ozempic Fat loss in the cheeks and jawline, common side effects of rapid weight loss, can cause gums to appear more prominent and smiles to look aged or sunken. For many, this creates a cruel irony: achieving the body they wanted while potentially compromising the smile they once loved. This shift reflects our ever-evolving beauty standards, where one "fix" can inadvertently create another perceived flaw. As Dr. Sandra García Martin, founder of DR. S LONDON on Harley Street, observes, she's witnessing increasing numbers of patients seeking solutions for oral health issues that weren't present before their weight loss journey began. The Medical Reality Behind "Ozempic Mouth" The dental changes associated with GLP-1 drugs extend far beyond cosmetic concerns. Dr. Martin has documented a range of oral health issues in her patients, including xerostomia (chronic dry mouth) leading to reduced saliva production, gum inflammation and recession that can permanently alter smile appearance, delayed healing following dental procedures like extractions or implant placement, altered taste sensation affecting eating habits and oral care, and increased tooth decay due to reduced protective saliva. "Dentists should check for signs of xerostomia, increased caries, gingival inflammation, and tooth wear suggesting bruxism that wasn't there previously," Dr. García Martin explains. The mechanism behind these changes is multifaceted. Ozempic's appetite-suppressing effects often lead to reduced fluid intake and dehydration. Additionally, according to Harvard Medical School, the gastrointestinal side effects including nausea, vomiting, and silent reflux expose teeth to harmful stomach acids. Many patients unknowingly worsen the problem by consuming acidic beverages like citrus water or flavored teas to combat nausea. Professional Solutions To Prevent and Treat "Ozempic Mouth" Dental professionals are developing targeted approaches to address these challenges. Dr. Ali from Emerdency emphasizes the importance of protective strategies, explaining, 'We need to look at remineralization strategies such as gentle brushing, fluoride treatments, and avoiding brushing immediately after reflux episodes.' Immediate protective measures include prioritizing hydration throughout the day, rinsing with bicarbonate water or fluoride mouthwash after vomiting episodes, maintaining a balanced and nutrient-rich diet, avoiding sugary and acidic foods and beverages, and chewing sugar-free gum to stimulate saliva production. As Dr. Ali notes, "avoid sugary and acidic foods and book frequent dental check-ups to look out for early signs of gum issues or enamel wear. You can also chew sugar-free gum to help stimulate saliva and use fluoride toothpaste." Professional treatments may involve regular fluoride varnish applications, saliva stimulants for persistent dry mouth, antimicrobial rinses used judiciously to prevent staining, and protective restorations or composite bonding for severely damaged enamel. Dr. Martin adds that while these dental treatments can help, antimicrobial rinses should only be used for short periods as they can stain teeth. Don't ignore warning signs that could indicate serious dental damage. Contact your dentist immediately if you experience new cavities appearing rapidly, persistent dry mouth despite increased water intake, increased sensitivity to hot or cold temperatures, loose, cracked, or shifting teeth, or chronic bad breath that doesn't improve with oral hygiene. How Ozempic Can Impact Mental Health The mental health implications of Ozempic and other weight loss drugs cannot be understated. In a society where a bright, full smile is synonymous with youth, health, and attractiveness, changes to oral appearance can trigger significant anxiety and self-consciousness. Social media's relentless focus on aesthetic perfection only amplifies these concerns, creating pressure to address every perceived imperfection. As medical interventions become increasingly accessible, we must develop a more nuanced understanding of the trade-offs involved in pursuing physical transformation. The key is to make informed decisions with comprehensive support from medical and dental professionals.
